Gender differences in new hypoglycemic drug effects on renal outcomes: a systematic review
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Clinical Pharmacology"
DOI: 10.1080/17512433.2022.2055546
Abstract: ABSTRACT Introduction Lifetime diabetes risk is greater in women than in men. Women with diabetes mellitus (DM) have a greater prevalence of diabetic kidney disease (DKD) risk factors. The diagnosis of DM is often delayed… read more here.
Keywords: systematic review; renal outcomes; hypoglycemic drugs; gender ... See more keywords
Meta-analysis of the association between new hypoglycemic agents and digestive diseases
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000030072
Abstract: Background: New hypoglycemic agents include sodium-glucose cotransporter-2 inhibitors (SGLT2is), glucagon-like peptide 1 receptor agonists (GLP1RAs), and dipeptidyl peptidase-4 inhibitors (DPP4is). The association between each class of these new hypoglycemic drugs and the risks of various… read more here.
Keywords: meta analysis; kinds digestive; hypoglycemic agents; digestive diseases ... See more keywords
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.877797
Abstract: New hypoglycemic drugs, including glucagon-like peptide 1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose cotransporter 2 inhibitors (SGLT-2i), which brings more options for the treatment of type 2 diabetes (T2DM). They are generally… read more here.
Keywords: combination; heart failure; hypoglycemic drugs; new hypoglycemic ... See more keywords